Next Article in Journal
Contrast-Enhanced Spectral Mammography Assessment of Patients Treated with Neoadjuvant Chemotherapy for Breast Cancer
Previous Article in Journal
Radiotherapy or Surgery? Comparative, Qualitative Assessment of Online Patient Education Materials on Prostate Cancer
Review

New Insights into the Biology and Diagnosis of Splenic Marginal Zone Lymphomas

1
Institut de pathologie multi-sites, Hôpital Lyon Sud, Hospices Civils de Lyon, 69310 Pierre Bénite, France
2
Laboratoire d’hématologie, Hôpital Lyon Sud, Hospices Civils de Lyon, 69310 Pierre Bénite, France
3
INSERM-Unité Mixte de Recherche 1052 CNRS 5286, Team “Clinical and Experimental Models of Lymphomagenesis”, UCBL, Cancer Research Center of Lyon, Université Lyon, 69001 Lyon, France
4
Service d’hématologie, Hôpital Lyon Sud, Hospices Civils de Lyon, 69310 Pierre Bénite, France
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2021, 28(5), 3430-3447; https://doi.org/10.3390/curroncol28050297
Received: 13 August 2021 / Revised: 2 September 2021 / Accepted: 3 September 2021 / Published: 6 September 2021
(This article belongs to the Special Issue B Cell Lymphoma in the Spleen)
Splenic marginal zone lymphoma (SMZL) is a small B-cell lymphoma, which has been recognized as a distinct pathological entity since the WHO 2008 classification. It classically presents an indolent evolution, but a third of patients progress rapidly and require aggressive treatments, such as immuno-chemotherapy or splenectomy, with all associated side effects. In recent years, advances in the comprehension of SMZL physiopathology have multiplied, thanks to the arrival of new devices in the panel of available molecular biology techniques, allowing the discovery of new molecular findings. In the era of targeted therapies, an update of current knowledge is needed to guide future researches, such as those on epigenetic modifications or the microenvironment of these lymphomas. View Full-Text
Keywords: splenic marginal zone lymphoma; review; genetic; molecular splenic marginal zone lymphoma; review; genetic; molecular
Show Figures

Figure 1

MDPI and ACS Style

Donzel, M.; Baseggio, L.; Fontaine, J.; Pesce, F.; Ghesquières, H.; Bachy, E.; Verney, A.; Traverse-Glehen, A. New Insights into the Biology and Diagnosis of Splenic Marginal Zone Lymphomas. Curr. Oncol. 2021, 28, 3430-3447. https://doi.org/10.3390/curroncol28050297

AMA Style

Donzel M, Baseggio L, Fontaine J, Pesce F, Ghesquières H, Bachy E, Verney A, Traverse-Glehen A. New Insights into the Biology and Diagnosis of Splenic Marginal Zone Lymphomas. Current Oncology. 2021; 28(5):3430-3447. https://doi.org/10.3390/curroncol28050297

Chicago/Turabian Style

Donzel, Marie, Lucile Baseggio, Juliette Fontaine, Florian Pesce, Hervé Ghesquières, Emmanuel Bachy, Aurélie Verney, and Alexandra Traverse-Glehen. 2021. "New Insights into the Biology and Diagnosis of Splenic Marginal Zone Lymphomas" Current Oncology 28, no. 5: 3430-3447. https://doi.org/10.3390/curroncol28050297

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop